One big development in clinical trial design in acute myeloid leukemia (AML) is the inclusion of measurable residual disease (MRD) testing. In this interview, Christopher Hourigan, MD, DPhil, of the National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, discusses the importance of this as part of the response assessment, with the message that MRD testing will be a part of AML clinical trials moving forwards. He also touches upon how clinicians can keep up-to-date on current MRD consensus criteria. This video was recorded at the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden.
MRD testing will be a part of future AML clinical trials
